Aquestive Therapeutics (NASDAQ:AQST) Releases Earnings Results, Misses Expectations By $0.08 EPS

Aquestive Therapeutics (NASDAQ:AQST) released its quarterly earnings results on Tuesday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.08), FiscalAI reports. The company had revenue of $13.82 million for the quarter, compared to analyst estimates of $11.42 million.

Aquestive Therapeutics Stock Performance

Shares of NASDAQ AQST traded up $0.12 during mid-day trading on Tuesday, reaching $4.41. The company had a trading volume of 6,448,469 shares, compared to its average volume of 3,025,584. Aquestive Therapeutics has a one year low of $2.93 and a one year high of $7.55. The firm has a market cap of $553.32 million, a price-to-earnings ratio of -7.23 and a beta of 1.49. The business’s 50-day simple moving average is $4.12 and its 200 day simple moving average is $4.06.

Key Headlines Impacting Aquestive Therapeutics

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: Aquestive reported positive topline human-factors and pharmacokinetic study results for Anaphylm™ (dibutepinephrine) sublingual film. The findings indicated improvements in how users handled and administered the potential anaphylaxis treatment, supporting the product’s usability and regulatory prospects. Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm
• Positive Sentiment: The encouraging Anaphylm study news prompted a sharp move in the stock in the prior session, highlighting the candidate’s importance to Aquestive’s valuation. If development and regulatory milestones remain positive, Anaphylm could provide a significant future commercial opportunity. Aquestive Therapeutics shares jump after encouraging Anaphylm study results
• Neutral Sentiment: Aquestive released second-quarter 2026 financial results and a strategic business update. The announcement gives investors additional information on operating performance and Anaphylm development, but the supplied report does not include enough detail to assess the quarter’s results independently. Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Negative Sentiment: Aquestive’s updated fiscal 2026 revenue guidance of $46.0 million to $50.0 million is below the $50.8 million analyst consensus at the midpoint. The reduced outlook may weigh on sentiment by signaling slower-than-expected near-term revenue growth, although the positive Anaphylm data partially offsets the concern.

Insider Activity

In related news, Director Julie Krop sold 25,000 shares of the company’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $5.02, for a total transaction of $125,500.00. Following the completion of the sale, the director owned 25,000 shares of the company’s stock, valued at $125,500. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Barber sold 8,257 shares of the firm’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $4.29, for a total transaction of $35,422.53. Following the completion of the transaction, the chief executive officer directly owned 660,574 shares in the company, valued at approximately $2,833,862.46. This represents a 1.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.81% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in AQST. NewEdge Advisors LLC bought a new stake in Aquestive Therapeutics during the third quarter worth $28,000. BNP Paribas Financial Markets increased its stake in shares of Aquestive Therapeutics by 78.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock valued at $31,000 after purchasing an additional 4,134 shares during the last quarter. Modern Wealth Management LLC bought a new position in shares of Aquestive Therapeutics in the 2nd quarter valued at $33,000. Kestra Private Wealth Services LLC acquired a new position in shares of Aquestive Therapeutics during the 3rd quarter worth $60,000. Finally, Victory Capital Management Inc. raised its holdings in shares of Aquestive Therapeutics by 17.0% during the 3rd quarter. Victory Capital Management Inc. now owns 12,794 shares of the company’s stock worth $72,000 after buying an additional 1,862 shares in the last quarter. 32.45% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on AQST. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Friday, July 17th. Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Oppenheimer assumed coverage on shares of Aquestive Therapeutics in a research report on Friday, April 24th. They issued an “outperform” rating and a $8.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $8.50.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.